Binding of anticardiolipin antibodies to protein C via β2- glycoprotein I (β2-GPI): A possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system

Clinical and Experimental Immunology

Volumn 112, Issue 2, 1998, Pages 325-333

  Atsumi, T ^a   Khamashta, M A ^a   Amengual, O ^a   Donohoe, S ^b   Mackie, I ^b   Ichikawa, K ^c   Koike, T ^c   Hughes, G R V ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Antiphospholipid syndrome; Coagulation; Phospholipid binding protein; Thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; EPITOPE; IMMUNOGLOBULIN G; LUPUS ANTICOAGULANT; MONOCLONAL ANTIBODY; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE; PHOSPHOLIPID; PHOSPHOLIPID ANTIBODY; PHOSPHOLIPID BINDING PROTEIN; PROTEIN C;

ADOLESCENT; ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; RECURRENT ABORTION; SCHOOL CHILD; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0031801589     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00582.x     Document Type: Article

References (62)

1. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other 'antiphospholipid' antibodies. Blood 1994; 84:2854-67.
2. Roubey RAS. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996; 39:1444-54.
3. Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet 1993; 342:341-4.
4. Khamashta MA, Hughes GRV. Antiphospholipid antibodies and antiphospholipid syndrome. Curr Opin Rheumatol 1995; 7:389-94.
5. Galli M, Comfurius P, Maassen C et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335:952-3.
6. Matsuura E, Igarashi Y, Fujimoto M et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336:177-8.
7. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that induces a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87:4120-4.
8. Kato H, Enjyoji K. Amino acid sequence and location of the disulfide bonds in bovine β2-glycoprotein I. The presence of five Sushi domains. Biochem 1991; 30:11687-94.
9. Ichinose A, Bottenus RE, Davie EW. Structure of transglutaminase. J Biol Chem 1990; 265:13411-4.
10. Matsuura E, Igarashi M, Igarashi Y et al. Molecular definition of human β2-glycoprotein I (β2-GPI) by cDNA cloning and inter species differences of β2-GPI in alternation anticardiolipin binding. Int Immunol 1991; 3:1217-21.
11. Hunt JE, Krilis S. The fifth domain of β2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol 1994; 152:653-9.
12. Igarashi M, Matsuura E, Igarashi Y et al. Human β2-glycoprotein I as an anticardiolipin cofactor determined using deleted mutants expressed by a baculovirus system. Blood 1996; 87:3262-70.
13. Matsuura E, Igarashi Y, Yasuda T et al. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179:457-62.
14. Roubey RAS, Eisenberg RA, Harper MF, Winfield JB. 'Anticardiolipin' autoantibodies recognize β2-glycoprotein I in the absence of phospholipid. J Immunol 1995; 154:954-60.
15. Tsutsumi A, Matsuura E, Ichikawa K et al. Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39:1466-74.
16. Amengual O, Atsumi T, Khamashta M et al. Specificity of ELISA for antibody to β2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol 1996; 35:1239-43.
17. Nimpf J, Wurm H, Kostner M. Interaction of β2-glycoprotein I with human blood platelets: influences upon the ADP induced aggregation. Thromb Haemost 1985; 54:397-401.
18. Schousboe I, Rasmussen MS. Synchronized inhibition of the phospholipid mediated autoactivation of Factor XII in plasma by β2-glycoprotein I and anti-β2-glycoprotein I. Thromb Haemostas 1995; 73:798-804.
19. Schoushoe I. β2-glycoprotein I: plasma inhibitor of contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66:1086-91.
20. Shi W, Chong B, Hogg P, Chesterman C. Anticardiolipin antibodies block the inhibition by β2-glycoprotein I of the factor Xa generating activity of platelets Thromb Haemost 1993; 70:342-5.
21. Bancsi LF, van der Linden IK, Bertina RM. β2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost 1992; 67:649-53.
22. Benedetti ED, Reber G, Miescher PA. No increase of β2-glycoprotein I levels in patients with antiphospholipid antibodies. Thromb Haemost 1992; 68:624.
23. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264:4743-6.
24. Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalysed activation of protein C. Proc Natl Acad Sci USA 1981; 78:2249-52.
25. Esmon NL, Owen WG, Esmon CT. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1982; 257:859-64.
26. Suzuki K, Stenflo J, Dahlbäck B, Teodorsson B. Inactivation of human coagulation Factor V by activated protein C. J Biol Chem 1983; 258:1914-8.
27. Dahlbäck B. Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system. Thromb Haemost 1991; 66:49-61.
28. Griffin JH, Evatt B, Zimmerman TS et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68:1370-3.
29. Bertina RM, Koeleman BPC, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67.
30. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330:517-22.
31. de Groot PG, Derksen RHWM. Protein C pathway, antiphospholipid antibodies and thrombosis. Lupus 1994; 3:229-33.
32. Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989; 71:2426-32.
33. Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76:101-7.
34. Borrell M, Sala N, de Castellarnau C et al. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost 1992; 68:101-7.
35. Oosting JD, Derksen RHWM, Bobbink IWG et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S. An explanation for their pathogenic mechanism? Blood 1993; 81:2618-25.
36. Keeling DM, Wilson AJG, Mackie IJ et al. Role of β2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitro. J Clin Pathol 1993; 46:908-11.
37. Mori T, Takeya H, Nishioka J et al. β2-glycoprotien I modulates the anticoagulant activity of activated protein C on the phospholipid surface. Thromb Haemost 1996; 75:49-55.
38. Simioni P, Lazzaro A, Zanadri S, Girolami A, Spurious protein C deficiency due to antiphospholipid antibodies. Am J Hematol 1992; 36:299-300.
39. Matsuura E, Igarashi Y, Fujimoto M et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 1992; 148:3885-91.
40. Ichikawa K, Khamashta M, Koike T et al. Reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome to β2-glycoprotein I. Arthritis Rheum 1994; 37:1453-61.
41. Del PaPa N, Guidali L, Sala A et al. Endothelial cells as target for antiphospholipid antibodies. Arthritis Rheum 1997; 40:551-61.
42. Comp PC, de Bault LE, Esmon NL, Esmon CT. Human thromhomodulin is inhibited by IgG from two patients with non specific anticoagulants. Blood 1983; 62:299 (Abstr.).
43. Harris EN, Pierangeli SS. Functional effects of anticardiolipin antibodies. Lupus 1996; 5:372-7.
44. Cariou R, Tobelem G, Soria C, Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med 1986; 314:1193-4.
45. Cariou R, Tobelem G, Bellucci S et al. Effect of lupus anticoagulant on antithrombotic properties of endothelial cells - inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost 1988; 60:54-58.
46. Taskiris DA, Settas L, Makris PE, Marbet GA. Lupus anticoagulant-antiphospholipid antibodies and thrombophilia. Relation to protein C-protein S-thrombomodulin. J Rheumatol 1990; 17:785-9.
47. Oosting JD, Derksen RHWM, Hackeng TM et al. In vitro studies of antiphospholipid antibodies and its cofactor β2-glycoprotein I, show negligible effects on endothelial cell mediated protein C activation. Thromb Haemost 1991; 66:666-71.
48. Forastiero R, Kordich L, Basilotta E, Carreras L. Differences in protein S and C4b-binding protein levels in different groups of patients with antiphosphoplipid antibodies. Blood Coag Fibrinol 1994; 5:609-16.
49. Ginsberg J, Demers C, Brill-Edwards P et al. Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus. Am J Med 1995; 98:379-83.
50. Ames PRJ, Tommasino C, Iannaccone L et al. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies - a crucial role for acquired free protein S deficiency. Thromb Haemost 1996; 76:190-4.
51. Mitchell CA, Rowell JA, Hau L et al. A fatal thrombotic disorder associated with an acquired inhibitor of protein C. N Eng J Med 1987; 317:1620-42.
52. Ruiz-Argüelles A, Vazquez-Prado J, Deleze M et al. Presence of serum antibodies to coagulation protein C in patients with systemic lupus erythematosus is not associated with antigenic or functional protein C deficiencies. Am J Hematol 1993; 44:58-59.
53. Bakker HM, Tans G, Janssen-Claessen T et al. The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C. Eur J Biochem 1992; 208:171-8.
54. Pei G, Powers DD, Lentz, BR. Specific contribution of different phospholipid surfaces to the activation of prothrombin by the fully assembled prothrombinase. J Biol Chem 1993; 268:3226-33.
55. Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994; 269:816-9.
56. Simantov R, LaSala JM, Lo SK et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96:2211-9.
57. Tannenbaum SH, Finco R, Cines DB. Antibody and immune complexes induce tissue factor production by human endothelial cells. J Immunol 1986; 137:1532-7.
58. Atsumi T, Khamashta MA, Amengual O, Hughes GRV. Up-regulated tissue factor expression in antiphospholipid syndrome. Thromb Haemost 1997; 77:222-3.
59. Jurado M, Paramo JA, Gutierrez-Pimentel M, Rocha E. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders. Thromb Haemost 1992; 68:516-20.
60. Lellouche F, Martinuzzo M, Said P et al. Imbalance of thromboxane/ prostacyclin biosynthesis in patients with lupus anticoagulant. Blood 1991; 78:2894-9.
61. Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost 1996; 75:536-41.
62. Smirnov MD, Triplett DT, Comp PC et al. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995; 95:309-16.